TLR4 and COVID-19: Notably, a Japanese pharmaceutical company is participating in collaborative COVID-19 clinical trials to test the efficacy of a TLR4 antagonist, Eritoran (E5564), in reducing cytokine storm (Tsukahara, 2022).